Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

businesswire

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial – NEWSnet – News… as it used to be

More Press Releases

Featured image for Auto-prepared featured image

May 14, 2026

Jazzy Day Spa Introduces Glacē™ Treatment: A Gentle, Skin-Purifying Ritual for a Grounding, Glowing Complexion

May 14, 2026

A M Richards Glass Co Inc Highlights the Benefits of Modern Andersen Window Installation in Chesterfield, MO

May 14, 2026

EveryLife Foundation Scientific Workshop Advances Patient-Centered Approaches to Rare Disease Therapy Development

May 14, 2026

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Jazzy Day Spa Introduces Glacē™ Treatment: A Gentle, Skin-Purifying Ritual for a Grounding, Glowing Complexion

A M Richards Glass Co Inc Highlights the Benefits of Modern Andersen Window Installation in Chesterfield, MO

EveryLife Foundation Scientific Workshop Advances Patient-Centered Approaches to Rare Disease Therapy Development

Tracey Weber elected to Ally Financial board of directors